Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET

Company Participants

Mark Kinarney - VP of IR
Brian Markison - CEO
Paul Blanchfield - President
Bob Marshall - CFO
Jeff Humphrey - Chief Medical Officer

Conference Call Participants

Roanna Ruiz - Leerink Partners
Anthony Petrone - Mizuho Group
Richard Newitter - Truist Securities
Matt Taylor - Jefferies
Larry Solow - CJS Securities
Tara Bancroft - TD Cowen
Yuan Zhi - B. Riley
Kemp Dolliver - Brookline Capital Markets
Justin Walsh - Jones Trading
Andy Hsieh - William Blair
Ed Ridley-Day - Redburn Atlantic

Operator

Good morning. Welcome to the Lantheus Third Quarter 2024 Conference Call. All lines have been placed on mute. This call is being recorded and a replay will be available in the Investors section of the company's website approximately 2 hours after the completion of the call and will be archived for at least 30 days.

I'll now turn the call over to Mark Kinarney, Vice President of Investor Relations. Mark?

Mark Kinarney

Thank you. Good morning. With me today are Brian Markison, our CEO; Paul Blanchfield, our President; Bob Marshall, our CFO; Jeff Humphrey, our Chief Medical Officer; and Amanda Morgan, our Chief Commercial Officer.

We will begin with prepared remarks and then open the call for Q&A. This morning, we issued a press release, which was furnished to the SEC under Form 8-K reporting our third quarter 2024 results. The release and today's slide presentation are in the Investors section of our website. Any comments made could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties, which are detailed in our SEC filings. Discussions will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the Investors section of our website.

I will now turn the call over to our CEO, Brian.

Brian Markison

Thank you, Mark, and good morning, everyone. Lantheus is the leading radiopharmaceutical focused company with market leading commercial products and a growing radiopharmaceutical pipeline targeting areas of significant unmet need. In the third quarter, we continued to enhance our leadership and create long-term sustainable growth through operational excellence, financial discipline and prudent capital deployment. PYLARIFY, our PSMA PET imaging agent delivered solid performance and remains on track to reach blockbuster status in 2024. And DEFINITY, our ultrasound enhancing agent grew double-digits year-over-year. The continued success of these flagship diagnostic agents enables us to invest both organically and inorganically in our pipeline to extend our radiopharmaceutical leadership and create long-term value for shareholders.